Meeting: 2018 ASCO Annual Meeting Track: Lung Cancer—Non-Small Cell Metastatic Abstract number: 9025 Authors: Jonathan Wade Goldman, Julien Mazieres, Fabrice Barlesi, et. al. Background: Approximately 30% of NSCLC tumors harbor KRAS mutations, for which there is no specific treatment. Abemaciclib is a potent and selective inhibitor of CDK4 & 6 approved...
Pro zobrazení tohoto obsahu je třeba být přihlášen.